Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.
Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
- Details
- Category: Sanofi
Sanofi announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron.
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
- Details
- Category: AstraZeneca
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine widely accessible around the world in an equitable manner.
Johnson & Johnson announces collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate
- Details
- Category: Johnson & Johnson
Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed.
Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2.
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
- Details
- Category: AstraZeneca
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford.
More Pharma News ...
- Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
- Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
- Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
- AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
- Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
- Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- Boehringer Ingelheim steps up effort with Global Support Program